Genfit S.A. Cash Flow Conversion Efficiency
Genfit S.A. cash flow conversion efficiency. Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.212x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€5.01 Million ≈ $5.86 Million USD) by net assets (€-23.64 Million ≈ $-27.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genfit S.A. (2003–2025)
Cash flow conversion efficiency of Genfit S.A. from 2003 to 2025. This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Genfit S.A. for real-time trading data and today's change.
Genfit S.A. Cash Flow Conversion Ratio Explained
Genfit S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genfit S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency. Also see GNFT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
-0.304x |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
-0.042x |
|
V-Mart Retail Limited
NSE:VMART
|
0.007x |
|
Sichuan Tianyi Comheart Telecom Co Ltd Class A
SHE:300504
|
0.004x |
|
PT Super Bank Indonesia Tbk
JK:SUPA
|
0.213x |
|
Ningbo Exciton Technology Co Ltd
SHE:300566
|
0.052x |
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
0.011x |
|
Fujian Zhangzhou Development Co Ltd
SHE:000753
|
0.034x |
Annual Cash Flow Conversion Efficiency for Genfit S.A. (2003–2025)
The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2003 to 2025. Review Genfit S.A. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-23.64 Million ≈ $-27.64 Million |
€-25.32 Million ≈ $-29.61 Million |
1.071x | +376.83% |
| 2024-12-31 | €69.22 Million ≈ $80.93 Million |
€15.55 Million ≈ $18.18 Million |
0.225x | +127.54% |
| 2023-12-31 | €67.95 Million ≈ $79.44 Million |
€-55.43 Million ≈ $-64.80 Million |
-0.816x | -6.15% |
| 2022-12-31 | €94.53 Million ≈ $110.51 Million |
€-72.64 Million ≈ $-84.92 Million |
-0.768x | -191.60% |
| 2021-12-31 | €119.10 Million ≈ $139.24 Million |
€99.92 Million ≈ $116.81 Million |
0.839x | -85.93% |
| 2020-12-31 | €-16.16 Million ≈ $-18.90 Million |
€-96.37 Million ≈ $-112.67 Million |
5.963x | +1151.31% |
| 2019-12-31 | €84.06 Million ≈ $98.28 Million |
€-47.68 Million ≈ $-55.74 Million |
-0.567x | +78.82% |
| 2018-12-31 | €20.94 Million ≈ $24.48 Million |
€-56.08 Million ≈ $-65.56 Million |
-2.678x | -459.93% |
| 2017-12-31 | €104.23 Million ≈ $121.85 Million |
€-49.86 Million ≈ $-58.29 Million |
-0.478x | -150.88% |
| 2016-12-31 | €142.80 Million ≈ $166.94 Million |
€-27.23 Million ≈ $-31.83 Million |
-0.191x | +28.95% |
| 2015-12-31 | €55.42 Million ≈ $64.79 Million |
€-14.87 Million ≈ $-17.38 Million |
-0.268x | -21.99% |
| 2014-12-31 | €70.43 Million ≈ $82.34 Million |
€-15.49 Million ≈ $-18.11 Million |
-0.220x | +66.27% |
| 2013-12-31 | €14.09 Million ≈ $16.48 Million |
€-9.19 Million ≈ $-10.75 Million |
-0.652x | +43.31% |
| 2012-12-31 | €6.83 Million ≈ $7.99 Million |
€-7.86 Million ≈ $-9.19 Million |
-1.150x | +27.92% |
| 2011-12-31 | €4.46 Million ≈ $5.21 Million |
€-7.11 Million ≈ $-8.32 Million |
-1.596x | -148.23% |
| 2010-12-31 | €8.39 Million ≈ $9.81 Million |
€-5.39 Million ≈ $-6.31 Million |
-0.643x | -4415.44% |
| 2009-12-31 | €15.52 Million ≈ $18.14 Million |
€-221.00K ≈ $-258.37K |
-0.014x | +93.83% |
| 2008-12-31 | €22.38 Million ≈ $26.17 Million |
€-5.16 Million ≈ $-6.04 Million |
-0.231x | -21.55% |
| 2007-12-31 | €25.37 Million ≈ $29.66 Million |
€-4.81 Million ≈ $-5.63 Million |
-0.190x | -202.28% |
| 2006-12-31 | €27.77 Million ≈ $32.47 Million |
€-1.74 Million ≈ $-2.04 Million |
-0.063x | -150.16% |
| 2005-12-31 | €13.39 Million ≈ $15.65 Million |
€1.68 Million ≈ $1.96 Million |
0.125x | -54.99% |
| 2004-12-31 | €14.00 Million ≈ $16.37 Million |
€3.89 Million ≈ $4.55 Million |
0.278x | +43.82% |
| 2003-12-31 | €9.04 Million ≈ $10.57 Million |
€1.75 Million ≈ $2.04 Million |
0.193x | -- |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase… Read more